614730-97-1

Basic information

• Product Name: 1-BOC-4-FLUORO-4-(HYDROXYMETHYL)-PIPERIDINE
• Synonyms: 1-BOC-4-FLUORO-4-(HYDROXYMETHYL)-PIPERIDINE;1-PIPERIDINECARBOXYLIC ACID, 4-FLUORO-4-(HYDROXYMETHYL)-, 1,1-DIMETHYLETHYL ESTER;tert-butyl 4-fluoro-4-(hydroxymethyl)piperidine-1-carboxylate;4-fluoro-4-hydroxymethyl-piperidine-1-carboxylic acid tert-butyl ester;1-Boc-4-fluoro-4-(hydroxy...
• CAS NO: 614730-97-1
• Molecular Formula: C₁₁H₂₀FNO₃
• Molecular Weight: 233.28
• Mol File: 614730-97-1.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 311.017 °C at 760 mmHg
• Flash Point: 141.898 °C
• Appearance: /
• Density: 1.137 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.481
• Storage Temp.: 2-8°C
• PKA: 14.94±0.10(Predicted)
• CAS DataBase Reference: 1-BOC-4-FLUORO-4-(HYDROXYMETHYL)-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-FLUORO-4-(HYDROXYMETHYL)-PIPERIDINE(614730-97-1)
• EPA Substance Registry System: 1-BOC-4-FLUORO-4-(HYDROXYMETHYL)-PIPERIDINE(614730-97-1)

Safety Data

• Hazardous Substances Data: 614730-97-1(Hazardous Substances Data)

Usage

Description

1-BOC-4-FLUORO-4-(HYDROXYMETHYL)-PIPERIDINE, also known as tert-Butyl 4-Fluoro-4-(hydroxymethyl)piperidine-1-carboxylate, is an organic compound with a molecular structure that features a piperidine ring substituted with a fluorine atom, a hydroxymethyl group, and a tert-butyl carbamate (BOC) protecting group. 1-BOC-4-FLUORO-4-(HYDROXYMETHYL)-PIPERIDINE is significant in the field of medicinal chemistry due to its potential applications in the development of pharmaceuticals.

Uses

Used in Pharmaceutical Industry:
1-BOC-4-FLUORO-4-(HYDROXYMETHYL)-PIPERIDINE is used as a key intermediate in the synthesis of heterocyclic compounds, specifically as BCL-2 inhibitors. BCL-2 is a protein that prevents apoptosis (cell death) and is overexpressed in various types of cancer cells, making it a promising target for cancer therapy. By inhibiting BCL-2, these heterocyclic compounds can potentially induce apoptosis in cancer cells, leading to the treatment of various types of cancer.

InChI:InChI=1/C11H20FNO3/c1-10(2,3)16-9(15)13-6-4-11(12,8-14)5-7-13/h14H,4-8H2,1-3H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 614731-04-3 1-[(tert-butoxy)carbonyl]-4-fluoropiperidine-4-carboxylic acid 
• 416852-82-9 4-fluoropiperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester 
• 147804-30-6 1-oxa-6-aza-spiro-[2.5]octane-6-caboxylic acid tert-butyl ester 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 

Downstream Products

• 1137478-13-7 tert-butyl 4-((2-(5-cyanopyrazin-2-ylamino)-5-(4-methoxyphenyl)pyridin-4-ylamino)methyl)-4-fluoropiperidine-1-carboxylate 
• 1137478-12-6 5-(4-((4-fluoropiperidin-4-yl)methylamino)-5-(4-methoxyphenyl)pyridin-2-ylamino)pyrazine-2-carbonitrile 
• 1137478-11-5 tert-butyl 4-((2-chloro-5-(4-methoxyphenyl)pyridin-4-ylamino)methyl)-4-fluoropiperidine-1-carboxylate 
• 620611-27-0 4-aminomethyl-4-fluoro-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Design, synthesis, and evaluation of a novel 4-aminomethyl-4- fluoropiperidine as a T-type Ca2+ channel antagonist

The novel T-type antagonist (S)-5 has been prepared and evaluated in in vitro and in vivo assays for T-type calcium ion channel activity. Structural modification of the piperidine leads 1 and 2 afforded the fluorinated piperidine (S)-5, a potent and selec

Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate

The acetylcholinesterase (AChE) inhibitors remain key therapeutic drugs for the treatment of Alzheimer's disease (AD). However, the low-safety window limits their maximum therapeutic benefits. Here, a novel kinetics-driven drug design strategy was employed to discover new-generation AChE inhibitors that possess a longer drug-target residence time and exhibit a larger safety window. After detailed investigations, compound 12 was identified as a highly potent, highly selective, orally bioavailable, and brain preferentially distributed AChE inhibitor. Moreover, it significantly ameliorated cognitive impairments in different mouse models with a lower effective dose than donepezil. The X-ray structure of the cocrystal complex provided a precise binding mode between 12 and AChE. Besides, the data from the phase I trials demonstrated that 12 had good safety, tolerance, and pharmacokinetic profiles at all preset doses in healthy volunteers, providing a solid basis for its further investigation in phase II trials for the treatment of AD.

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.